

## CANDIDATURA IN VISTA DEL CONFERIMENTO DEL GRADO DI PROFESSORE TITOLARE

Dr. med. XXX YYYY

Funzione

Servizio

Ospedale

Luogo

Nazione

### CURRICULUM VITAE PROFESSIONALE

#### Dati anagrafici

Data di nascita: \_\_\_\_\_

Luogo di origine: \_\_\_\_\_

Nazionalità: \_\_\_\_\_

Email: \_\_\_\_\_

Indirizzo professionale: \_\_\_\_\_

Indirizzo privato: \_\_\_\_\_

#### Formazione preuniversitaria

-19XX-19XX Scuole elementari, Luogo (Nazione)

-19XX-19XX Scuole Medie, Luogo (Nazione)

-19XX-19XX Liceo Cantonale, Luogo (Nazione)

#### Formazione universitaria

-19XX-19XX Università di Luogo (Nazione)

-19XX-20XX Università di Luogo (Nazione)

#### Conoscenze linguistiche

XXXX (lingua madre), YYYYY, ZZZZ

#### Posizioni postuniversitarie

- 1.1.20XX-31.12.20XX: medico assistente, Reparto XXX, Ospedale XXXX, Nazione (direttore: Prof. Dr. med. XXXXX).

- 1.1.20XX-31.12.20XX: medico capo-clinica, Reparto XXX, Ospedale XXXX, Nazione (direttore: Prof. Dr. XXXX).

- da 1.1.20XX: medico caposervizio, Servizio XXXX, Ospedale XXXX, Luogo Nazione (direttore: Dr. med XXXX).

#### Formazione di ricerca

- Laboratorio di ricerca XXXXXX, Ospedale, Luogo, Nazione (responsabile: Prof. Dr. XXXX).

- Laboratorio di ricerche XXXXX, Clinica XXXX, Luogo, Nazione (responsabile: Prof. Dr. XXXXX).

## **Diplomi**

- 19XX Maturità XXXXXXXXXXXX
- 20XX Diploma XXXXXXXXXXXX
- 20XX Dottorato XXXXXXXXX
- 20XX Titolo specialità XXXXXXXXX
- 20XX Venia legendi (libera docenza) – Università XXXX
- 20XX Corso di didattica medica “teach the teacher” Luogo

## **Membro delle seguenti società professionali**

- Società svizzera XXX
- Società svizzera VVVV
- Società europea YYYY

## **Consulenze per riviste scientifiche**

### **- “Reviewer”**

Nome della rivista – nome della rivista – nome della rivista.

### **- Comitato di redazione (“Editorial Board”) di riviste scientifiche**

XXXXX (20XX-20XX)

## **Riconoscimenti**

Premio XXXX 20XX della Società Svizzera di XXXXX

## **Esperienza didattica (2 anni prima della candidature)**

- Relatore ai corsi di aggiornamento interni del Servizio di XXXX, Ospedale XXXXX, Luogo (circa 6 presentazioni all'anno)
- Relatore al corso di aggiornamento in XXXXXX del Luogo (20XX)
- Presentazioni orali al congresso della Società XXXX (20XX e 20XX)
- Presentazione di 2 poster all'American XXXX Society (Luogo, 20XX)
- Case-based learning settimanale dell'Ospedale XXXXX (direzione: Prof. Dr. med. XXXX)

## **PRODUZIONE SCIENTIFICA**

- **Direzione di tesi di master:** X. YYYY (20XX), Y. ZZZZ (20XX), Z. VVVVV (20XX), V. WWW(20XX)
- **Direzione di tesi (MD):** Y. XXX (20XX), Z. YYYY (20XX), V. WWW (20XX)
- **Fondi di ricerca**
  - 20XX: Fondo di ricerca della Società XXXX (Tema; CHF XX'XXX.00)
  - 20XX: Borsa della Fondazione XXX (CH XX'XXX)

## Lavori scientifici pubblicati in riviste con politica editoriale

• **Fattore di Hirsch (Scopus, verificato il XX.X.XX): Y**

• **Lavori originali e reviews sistematiche**

### Prima del conferimento della venia legendi

1. **Viviani CF**, Mascetti L, Bettazzi A, Simoni GD, Taglioni A, Syrén ML, Nordio F. Pregnancy in inherited hypokalemic salt-losing renal tubular disorder. *Obstet Gynecol* 117: 512-516, 2002. **Impact factor/maximum ranking 2016: 4.982 / 0.951**
2. **Viviani CF**, Zgraffen L, Faré PB, Müller SA, Simoni GD, Fossoni EF, Amoroso C. Palatability of crushed  $\beta$ -blockers, converting enzyme inhibitors and thiazides. *J Clin Pharm Ther* 37: 544-546, 2003. **Impact factor/maximum ranking 2016: 1.661 / 0.227**
3. Bullo M, Tschumi S, Bucher BS, **Viviani CF**, Simoni GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. *Hypertension* 60: 444-450, 2003. **Impact factor/maximum ranking 2016: 6.823 / 0.969**
4. Terrorista L, Müller SAG, Camozzi P, Zraggen L, Simoni GD, **Viviani CF**, Torino GP. Unusual eruptions associated with *Mycoplasma pneumoniae* respiratory Infections: review of the literature. *Dermatology* 231: 152-157, 2003. **Impact factor/maximum ranking 2016: 1.958 / 0.556**
5. **Viviani CF**, Janett S, Camozzi P, Peeters GGAM, Müller SAG, Simoni GD, Simonari B, Torino GP. Hypomagnesemia induced by long-term treatment with proton-pump inhibitors. *Gastroenterol Res Pract* 2015:951768, 2004. **Impact factor/maximum ranking 2016: 1.859 / 0.212**
6. Müller C, Camozzi P, Renzo S, Müller SAG, Simoni GD, **Viviani CF**, Torino GP. Breastfeeding-associated hypernatremia: a systematic review of the literature. *J Hum Lact* 32:67-74, 2016. **Impact factor/maximum ranking 2016: 1.836 / 0.849**
7. **Viviani CF**, Helbling R, Müller SAG, Simoni GD, Camozzi P, Torino GP. Gallbladder and pancreas in Henoch-Schönlein purpura: Systematic review of the literature. *J Pediatr Gastroenterol Nutr* 62:457-461,2005. **Impact factor/maximum ranking 2016: 2.752 / 0.823**
8. Ferrarini A, Benetton C, Camozzov P, Ostinelli A, Simoni GD, Torino GP, **Viviani CF**, Müller SAG. Acute hemorrhagic edema of young children: a prospective case series. *Eur J Pediatr* 175:557-561,2006. **Impact factor/maximum ranking 2016: 2.242 / 0.669**
9. **Viviani CF**, Viano FA, Mazzoni MBM, Peeters GGAM, Fossoni EF, Camozzi P, Torino GP. Micro- and macroscopic hematuria caused by renal vein entrapment: systematic review of the literature. *Pediatr Nephrol* 31:175-184, 2008. **Impact factor/maximum ranking 2016: 2.627 / 0.79**
10. Santini M, Torino GP, Simoni GD, Fossoni EF, **Viviani CF**, Müller SAG. Magnesium in cystic fibrosis – Systematic review of the literature. *Pediatr Pulmonol* 51:196-202, 2008. **Impact factor/maximum ranking 2016: 3.157 / 0.887**
11. Santini M, Müller SAG, Simoni GD, Stettbacher A, **Viviani CF**, Muggli F. Clustering of cardiovascular disease risk factors among male youths in Southern Switzerland: preliminary study. *Swiss Med Wkly*: accepted for publication. *Swiss Med Wkly* 146:w14338, 2008. **Impact factor/maximum ranking 2016: 1.928 / 0.61**
12. **Viviani CF**, Müller SAG, Helbling R, Simoni GD, Torino GP. Pancreatitis and cholecystitis in primary acute symptomatic Epstein-Barr virus infection – Systematic review of the literature. *J Clin Virol* 82:51-55, 2008. **Impact factor/maximum ranking 2016: 3.101 / 0.571**
13. Saponetta A, Gondoni E, Cavallari R, Collina AM, Lombardi F, **Viviani CF**. Sporadic acute benign calf myositis: Systematic literature review. *Neuromuscul Disord* 28: 443-449, 2009. **Impact factor/maximum ranking 2016: 2.487 / 0.457**
14. Alentini P, Giavarini A, **Viviani CF**, Gondoni E, Cavallari R, Collina AM, Lombardi F. Cardiovascular profile of propranolol after multiple dosing in infantile hemangioma. *J Virol* 156:126-131, 20010. **Impact factor/maximum ranking 2016: 4.368 / 0.8**

### Dopo del conferimento della venia legendi

15. Lavoratori CM, Romani GP, Lavastoviglie SAG, **Viviani CF**, Biancardi MG, Simoni GD, Giannoni O. Hyperammonemia associated with recessive polycystic kidney disease: a systematic review. *Pediatr Nephrol* 2010;33(3):485-491. **Impact factor/maximum ranking 2016: 2.627 / 0.79**
16. Bianchi MG, Bettinardi A, Casez JP, Basilio E, Menta MG, Spichiger I, **Viviani CF**, Bigoni M, Jäger P. Evidence for disturbed regulation of calciotropic hormone metabolism in sarcoidosis. *J Clin Endocrinol Metab* 2011;80: 224-228. **Impact factor/maximum ranking 2016: 5.789 / 0.866**
17. Hafen G, Laux-End R, Truttmann AC, Schibler A, McGuigan JAS, **Viviani CF**. Circulating ionized magnesium during hyperventilation in healthy subjects. *Clin Sci* 2011;91: 347-351. **Impact factor/maximum ranking 2016: 5.22 / 0.88**
18. Villiger RM, von Vigier RO, Ramelli GP, Hassink RI, **Viviani CF**. 42 cases of erythema nodosum in sarcoidosis. *Eur J Pediatr* 2012;158: 929-932. **Impact factor/maximum ranking 2016: 2.242 / 0.669**
19. Leeaphorn N, Stokes MB, Ungprasert P, Lecatess W, **Viviani CF**. Management of granulomatous interstitial nephritis with mycophenolate mofetil: a multicenter inquiry. *Am J Kidney Dis* 2012;63:696-701. **Impact factor/maximum ranking 2016: 7.129 / 0.934**
20. Hamzeh N, Voelker A, Forssén A, Gottschall EB, Rose C, Mroz P, Maier LA, **Viviani CF**. Efficacy of mycophenolate mofetil in sarcoidosis: preliminary data. *Respir Med* 2013;108:1663-1669. **Impact factor/maximum ranking 2016: 3.31 / 0.701**
21. Tomnar RP, Rossi R, **Viviani CF**. Metabolic acidosis due to inhaled salbutamol: systematic literature review. *Respir Med* 2015;111:103-109. **Impact factor/maximum ranking 2016: 3.31 / 0.701**
22. **Viviani CF**,William JH, Scott DJ, Lee A, Howell MM, Cello DA, Mukammal AB. Proton-pump inhibitor use is associated with low magnesium concentrations in patients affected with asthma. *Am J Respir Med* 2016;119:345-352. **Impact factor/maximum ranking 2016: 7.129 / 0.934**

23. Snider MA, Wan JA, Kink R, Gilmores A, Arnold SR, **Viviani CF**. A randomized trial comparing metered dose inhalers and breath actuated nebulizers. *J Emerg Med* 2017;55:77-84. **Impact factor/maximum ranking 2016: 1.207 / 0.423**
24. **Viviani CF**, Howe A, Jaalam K, Ahmad B, Sheng C, Rahman D. The use of capnography to monitor non-intubated patients presenting with asthma. *J Emerg Med* 2018;41:81-87. **Impact factor/maximum ranking 2016: 1.207 / 0.423**

#### • Case reports – letters

##### Prima del conferimento della venia legendi

1. Torino GP, Dellepiane RM, Castellazzi ML, Mazzoni MBM, **Viviani CF**, Fossoni EF. Episodic idiopathic systemic capillary leak syndrome in a girl. *Pediatr Int* 2006;55: e81-e82. **Impact factor/maximum ranking 2016: 0.86 / 0.121**
2. **Viviani CF**, Müller SA, Simoni GD. Using ibuprofen to treat croup in six children presented to an emergency unit. *Acta Paediatr* 2007;102: e352. **Impact factor/maximum ranking 2016: 2.58 / 0.782**
3. **Viviani CF**, Kessler C, Tschumi S, Simoni GD. New-onset bone marrow aplasia in a 15-year-old adolescent with pauci-immune crescentic glomerulonephritis. *Acta Paediatr* 30:1265-1268, 2015. **Impact factor/maximum ranking 2016: 2.58 / 0.782**
4. **Viviani CF**, Camozzai P, Faré PB, Müllergno C, Torino GP, Fossoni EF, Müller SAG. Italo-Swiss "Chalk and blackboard interactive 2-day workshop" - participants feedback. *Ital J Pediatr* 2009;41:60. **Impact factor/maximum ranking 2016: 1.776 / 0.532**

##### Dopo il conferimento della venia legendi

5. **Viviani CF**, Camozzai P. Lactate clearance and beta-agonist-induced elevated lactates in asthma. *Internet J Pneumol* 2015;4:127-131. **Impact factor/maximum ranking 2016: 0.314 / 0.234**

#### • Reviews narrative

##### Prima del conferimento della venia legendi

1. Bucher BS, Ferrarini A, **Viviani CF**, Weber N, Bullo M, Simoni GD. Primary hypertension in childhood. *J Hypertens* 2008;15: 444-452. **Impact factor/maximum ranking 2016: 4.092 / 0.846**
2. Müller SAG, Simoni GD, Bianchetti AA, **Viviani CF**, Ferrarini A. Prevention of vitamin D insufficiency in Switzerland: A never-ending story. *Int J Pharm* 2008;457: 353-356. **Impact factor/maximum ranking 2016: 3.862 / 0.827**
3. Müller SAG, **Viviani CF**, Simoni GD. Salt intake in children and its consequences on blood pressure. *Pediatr Nephrol* 2010;30:1389–1396 **Impact factor/maximum ranking 2016: 2.627 / 0.79**
4. **Viviani CF**, Bucher BS, Simoni GD. Controversy about hypertension screening in children: a clinical perspective. *J Hypertens* 2010;33:1356-1358. **Impact factor/maximum ranking 2016: 4.092 / 0.846**
5. **Viviani CF**, Santon M, Müller SAG, Camozzov P, Giannelli O, Torino GP, Simoni GD, Fossoni EF, Faré PB. The great fluid debate: saline or balanced salt solutions? *Ital J Pediatr* 41:47, 2016. **Impact factor/maximum ranking 2016: 1.776 / 0.532**
6. Bertinotti A, Torino GP, Simoncelli GD, Fossoni EF, Faré PB, **Viviani CF**, Müller SAG. Na<sup>+</sup>, K<sup>+</sup>, Cl<sup>-</sup>, acid-base or H<sub>2</sub>O homeostasis in infants with bronchiolitis: narrative review. *Pediatr Nephrol* 31:1403–1409, 2017. **Impact factor/maximum ranking 2016: 2.627 / 0.79**

##### Dopo il conferimento della venia legendi

7. Bertinotti A, Brescia GP, Fossoni EF, Faré PB, **Viviani CF**. Sarcoidosis: current management. *Pneumology* 2017;23:555-561. **Impact factor/maximum ranking 2016: 2.500 / 0.600**
8. **Viviani CF**, James WE, Baughman R. Treatment of sarcoidosis: grading the evidence. *m Expert Rev Clin Pharmacol*. 2018;30:51-63. **Impact factor/maximum ranking 2016: 2.758 / 0.569**